ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Merus NV

Merus NV (2GH)

41.80
0.399999
( 0.97% )
Updated: 23:26:19
Realtime Data

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
41.80
Bid
41.40
Offer
42.40
Volume
405
41.80 Day's Range 42.20
21.40 52 Week Range 58.50
Previous Close
41.40
Open
41.80
Last Trade
32
@
41.799999
Last Trade Time
22:54:05
Average Volume (3m)
150
Financial Volume
-
VWAP
-

2GH Latest News

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-3.800001-8.3333355263245.645.639.650741.91558185DE
4-6.400001-13.278010373448.248.239.617842.85404101DE
12-3.400001-7.5221261061945.251.539.615046.14471602DE
26-7.200001-14.69387959184957.539.616948.03577184DE
5219.79999989.99999545452258.521.39999917944.24911102DE
15617.99999975.630247899223.858.51917141.97393714DE
26017.99999975.630247899223.858.51917141.97393714DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CXFChimerix Inc
1.98 €
(143.24%)
140.4k
UQ1Uniqure NV
13.50 €
(95.26%)
496
XE7CCardiff Oncology Inc
3.105 €
(34.42%)
55.93k
1TGTriton Minerals Ltd
0.006 €
(33.33%)
50.04k
DJDADieteren Group
163.50 €
(26.74%)
1.81k
0PV2Moovly Media Inc
0.0025 €
(-58.33%)
560
3RITurmalina Metals Corp
0.0102 €
(-53.21%)
300
PA8Paion AG
0.0132 €
(-45.90%)
784
UH7ATennant Minerals NL
0.0055 €
(-26.67%)
20k
N790Blackbird Critical Metals Corp
0.0115 €
(-25.81%)
4k
AXIAtos SE
0.0024 €
(-11.11%)
362.24M
D7GNel ASA
0.2739 €
(1.48%)
2.2M
PF8European Lithium Limited
0.0244 €
(-8.96%)
1.66M
3CPXiaomi Corporation
3.816 €
(-2.03%)
1.23M
24YBrainchip Holdings Ltd
0.1567 €
(13.72%)
699.14k

Discussion

View Full Feed
glenn1919 glenn1919 2 minutes ago
SOAR......VRAR.......IDAI...............https://stockcharts.com/h-sc/ui?s=SOAR&p=D&yr=0&mn=2&dy=12&id=p84071410134
IDAI VRAR
3Angels120702 3Angels120702 2 minutes ago
News for Blagman s Media Fusion company but nothing dealing with MWWC I'd dare say.
MWWC
Guzzi62 Guzzi62 2 minutes ago
I did read the JAMA journal and read what combo trials can do to survival.

Management is totally hopeless since they didn't manage to partner like +10 years ago.

I suspect it's their own greed that's the culprit, they likely wanted an unrealistic deal with BP, but the
AVXL
tw0122 tw0122 2 minutes ago
$13.71 + 88%
QURE
knrorrel knrorrel 3 minutes ago
$CDIO , too $HAO on watch
CDIO HAO
Methinks Methinks 3 minutes ago
https://thehackernews.com/2024/12/the-future-of-network-security.html
Wave could reduce this, totally.
tw0122 tw0122 3 minutes ago
Colorectal cancer positive results and offering at $2.60
$3.22 +'30%
CRDF
penguin007 penguin007 3 minutes ago
I think in this case, shrinkage is a good thing. lol
ZHUD
glenn1919 glenn1919 3 minutes ago
MNY......MULN...........................https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
MNY MULN
penguin007 penguin007 4 minutes ago
Check it today.
ZHUD
fliegenfranz1 fliegenfranz1 4 minutes ago
cd'er hub in russia got raided....y'all wont hear to much of them for awhile....thats why nutjob research is so mad....
AXXA
Methinks Methinks 5 minutes ago
https://www.scworld.com/perspective/why-gift-card-scams-are-getting-trickier-to-spot
Wave could be even trickier!
knrorrel knrorrel 6 minutes ago
$CDIO , too $HAO on watch
CDIO HAO
tw0122 tw0122 7 minutes ago
$4s against + 50%
TRNR
Uncle Monkey Uncle Monkey 8 minutes ago
funny that fake news pushers in hiding.
CBRF
glenn1919 glenn1919 8 minutes ago
PVPH.....PCSA......NBTX.....NRDY......CMRX.....CPIX......https://stockcharts.com/h-sc/ui?s=PVPH&p=D&yr=0&mn=2&dy=12&id=p84071410134
CMRX CPIX NBTX
backtoreality backtoreality 8 minutes ago
Back in the day there were "swing" traders and we made money. Now there is no such thing, OTC is ruined by the tic watchers that have all day to play.

Appreciate the support
RDAR
Uncle Monkey Uncle Monkey 8 minutes ago
so done deal? FSar today?
CBRF
buysellrepeat buysellrepeat 9 minutes ago
I'm still shocked by lack of Interest here. I guess no one knows about it yet. Our first full reporting Q had over $3M in revs. $12M a year based on them all being similar.  Market cap under a $1M. 
ATWT
peanutz peanutz 9 minutes ago
Me too ! Was going to exit at 15+ but there is much more in the tank . Wouldn't be surprised to see NVDA invest more here .
NVDA
Polymer Paul Polymer Paul 10 minutes ago
Perfect venue for lebby... In his element and I'm not on about photonics! Sausage jockey!
LWLG
biowin biowin 10 minutes ago
Here is the evidence Bioamber Inc is active company in US

There is an officer available also
https://opencorporates.com/companies/us_de/4612067

https://opencorporates.com/companies/us_de?action=search_companies&commit=Go&controller=searches&inactive=false&order=&
Zardiw Zardiw 11 minutes ago
Meteor Story:

214 Million years ago a 5km diameter Asteroid hit in Quebec. (Manicouagan impact event)

The asteroid landed on a mostly iron deposit, which contained graphite.

It melted the iron deposit, which took over 600 years to cool.

O
TORVF
StayHumble StayHumble 12 minutes ago
🇺🇸Hearing a MOASS takes $DJT to MARS🇺🇸wow!🇺🇸🇺🇸🇺🇸
DJT